TSE:4568Pharmaceuticals
How Investors Are Reacting To Daiichi Sankyo Company (TSE:4568) New Biomarker-Guided DATROWAY Lung Cancer Trial
In January 2026, Daiichi Sankyo and AstraZeneca dosed the first patient in the TROPION-Lung17 phase 3 trial, testing DATROWAY against docetaxel in TROP2 NMR positive, previously treated, advanced nonsquamous non-small cell lung cancer across Asia, Europe and North America.
This trial not only adds a ninth phase 3 program for DATROWAY in lung cancer, but also pioneers the prospective use of AstraZeneca’s Quantitative Continuous Scoring-based TROP2 NMR biomarker to potentially refine patient...